UNITED THERAPEUTICS Corp (UTHR) stock
UTHRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/3022% above fair value
$584.10−3.78 (-0.64%)
Close on Nov 17, 2026Market cap $25.05BP/E 20.9Yield –
United Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
United Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $551.50M, up 6.0% year over year. For fiscal 2025 it was $550.00M, up 14.3% from the year before. Over ten years it grew 8.4% a year on average. The highest annual figure on record is $1.18B in fiscal 2019.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $550.00M | +14.3% |
| FY2024 | Dec 31, 2024 | $481.00M | +17.9% |
| FY2023 | Dec 31, 2023 | $408.00M | +26.4% |
| FY2022 | Dec 31, 2022 | $322.90M | -40.2% |
| FY2021 | Dec 31, 2021 | $540.10M | +51.0% |
| FY2020 | Dec 31, 2020 | $357.70M | -69.8% |
| FY2019 | Dec 31, 2019 | $1.18B | +230.4% |
| FY2018 | Dec 31, 2018 | $357.90M | +35.3% |
| FY2017 | Dec 31, 2017 | $264.60M | +79.3% |
| FY2016 | Dec 31, 2016 | $147.60M | -39.8% |
| FY2015 | Dec 31, 2015 | $245.10M | +1.1% |
| FY2014 | Dec 31, 2014 | $242.50M | -19.0% |
| FY2013 | Dec 31, 2013 | $299.35M | +72.6% |
| FY2012 | Dec 31, 2012 | $173.39M | -3.7% |
| FY2011 | Dec 31, 2011 | $180.02M | +8.9% |
| FY2010 | Dec 31, 2010 | $165.31M | +37.3% |
| FY2009 | Dec 31, 2009 | $120.37M | -49.7% |
| FY2008 | Dec 31, 2008 | $239.18M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $146.30M | +9.2% |
| Q1 FY2026 | Mar 31, 2026 | $138.20M | -7.2% |
| Q4 FY2025 | Dec 31, 2025 | $139.50M | +4.3% |
| Q3 FY2025 | Sep 30, 2025 | $127.50M | +23.2% |
| Q2 FY2025 | Jun 30, 2025 | $134.00M | -4.0% |
| Q1 FY2025 | Mar 31, 2025 | $149.00M | +43.1% |
| Q4 FY2024 | Dec 31, 2024 | $133.80M | -11.6% |
| Q3 FY2024 | Sep 30, 2024 | $103.50M | +22.2% |
| Q2 FY2024 | Jun 30, 2024 | $139.60M | +56.9% |
| Q1 FY2024 | Mar 31, 2024 | $104.10M | +25.6% |
| Q4 FY2023 | Dec 31, 2023 | $151.40M | +61.2% |
| Q3 FY2023 | Sep 30, 2023 | $84.70M | +28.1% |
| Q2 FY2023 | Jun 30, 2023 | $89.00M | -5.2% |
| Q1 FY2023 | Mar 31, 2023 | $82.90M | +20.1% |
| Q4 FY2022 | Dec 31, 2022 | $93.90M | +13.3% |
| Q3 FY2022 | Sep 30, 2022 | $66.10M | -16.5% |
| Q2 FY2022 | Jun 30, 2022 | $93.90M | +26.4% |
| Q1 FY2022 | Mar 31, 2022 | $69.00M | -77.3% |
| Q4 FY2021 | Dec 31, 2021 | $82.90M | -34.3% |
| Q3 FY2021 | Sep 30, 2021 | $79.20M | +15.3% |
| Q2 FY2021 | Jun 30, 2021 | $74.30M | -17.2% |
| Q1 FY2021 | Mar 31, 2021 | $303.70M | +314.9% |
| Q4 FY2020 | Dec 31, 2020 | $126.10M | +11.0% |
| Q3 FY2020 | Sep 30, 2020 | $68.70M | -19.8% |
| Q2 FY2020 | Jun 30, 2020 | $89.70M | +4.4% |
| Q1 FY2020 | Mar 31, 2020 | $73.20M | -91.8% |
| Q4 FY2019 | Dec 31, 2019 | $113.60M | -18.2% |
| Q3 FY2019 | Sep 30, 2019 | $85.70M | -15.2% |
| Q2 FY2019 | Jun 30, 2019 | $85.90M | +4.4% |
| Q1 FY2019 | Mar 31, 2019 | $897.40M | +2413.7% |
| Q4 FY2018 | Dec 31, 2018 | $138.80M | +107.5% |
| Q3 FY2018 | Sep 30, 2018 | $101.10M | +120.3% |
| Q2 FY2018 | Jun 30, 2018 | $82.30M | – |
| Q1 FY2018 | Mar 31, 2018 | $35.70M | – |
| Q4 FY2016 | Dec 31, 2016 | $66.90M | – |
| Q3 FY2016 | Sep 30, 2016 | $45.90M | – |
See a number that looks wrong?